✦ LIBER ✦

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

✍ Scribed by Mahadevan, Daruka; Sutton, Gregory Ryan; Arteta-Bulos, Rafael; Bowden, Chris J.; Miller, Paul J. E.; Swart, Rachel Elizabeth; Walker, Mark S.; Haluska, Paul; Munster, Pamela N.; Marshall, John; Hamid, Omid; Kurzrock, Razelle

Book ID: 121544937
Publisher: Springer
Year: 2014
Tongue: English
Weight: 747 KB
Volume: 73
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-013-2372-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A dose finding, safety and pharmacokinet

A dose finding, safety and pharmacokinetic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as a single agent and in combination with docetaxel in patients with advanced solid tumours

✍ Soria, Jean Charles; Massard, Christophe; Lazar, Vladimir; Ozoux, Marie-Laure; M 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 358 KB

Phase 1 study of ganitumab (AMG 479), a

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

✍ Haruyasu Murakami, Toshihiko Doi, Nobuyuki Yamamoto… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 228 KB

Phase I study to evaluate multiple regim

Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors : A potential broadly active regimen for advanced solid tumor malignancies

✍ Sridhar Mani; Nicholas J. Vogelzang; Donna Bertucci; Walter M. Stadler; Richard 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

234 A phase 1, open-label, dose-finding

234 A phase 1, open-label, dose-finding study to assess the safety and tolerability of U3 1287 (AMG 888), a human monoclonal antibody targeting HER3 in patients with advanced solid tumors

✍ P. LoRusso; V. Keedy; L. Yee; M. Oliveira; N. Rizvi; J. Berlin; X. Jin; T. Hettm 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 53 KB

A phase II, randomized, multicenter stud

A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer

✍ Christos Chouaid; Faith Nathan; Kristine Pemberton; Thomas Morris 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 244 KB

Efficacy, safety, and tolerability of a

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

✍ Robert P Giugliano; Nihar R Desai; Payal Kohli; William J Rogers; Ransi Somaratn 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 353 KB